Legacy Medical Consultants Acquires Right to Sell RedDress ActiGraft Pro, Broadening Its Strong Wound Care Portfolio Beyond Allografts

News provided by

Aug 19, 2025, 08:00 ET

FORT WORTH, Texas, Aug. 19, 2025 /PRNewswire/ -- Legacy Medical Consultants (LMC), a leading provider of allografts for the treatment of hard-to-heal chronic wounds, has acquired the U.S. rights to sell ActiGraft® wound care treatments, expanding its portfolio beyond allografts.

LMC reached agreement with RedDress, an Israel-based company, to exclusively market the product in the U.S. ActiGraft Pro is at the forefront of personalized and autologous wound care management, providing solutions for patients' most challenging chronic wounds.

The terms of the deal include exclusive agent status across all care settings, including hospitals, physician office, Veteran Affairs (VA) and Department of Defense (DoD) facilities, and outpatient wound-care centers. RedDress and Legacy will collaborate on payer‑coverage expansion, GPO contracting, and investigator‑initiated research to further validate ActiGraft's benefits.

Known as the silent epidemic, approximately 6.5 million – or 1 in 38 – adults are affected by chronic wounds each year in the U.S.¹ An aging population and the increase in rates of diabetes and obesity are major contributors to the dire need for continued innovation in the wound care space.

"As a leader in wound care, our mission at Legacy has always been to address unmet clinical needs. Through the evolution of science and innovation, we've been able to improve and expand treatment options for these patients to improve their quality of life," said Jonathan Knutz, LMC's Chief Executive Officer. "Patients shouldn't have to worry about having an amputated limb due to a chronic wound – they should have access to the best treatments. This is why our partnership with RedDress is so crucial. ActiGraft provides an option for patients, in addition to our high-quality allografts, that might not otherwise be available."

RedDress developed the innovative autologous solution, ActiGraft Pro, which offers a personalized approach to healing. Its technology uses a patient's own blood to create a whole blood clot, replacing a dysfunctional extracellular matrix (ECM) responsible for stalled wounds. This supports the reactivation of the innate healing process and the facilitation of a natural healing cascade. The ActiGraft can be used on patients who are taking a blood thinner and have exposed bones and tendons.

"Legacy Medical Consultants' high-quality team and Allograft portfolio is a powerful complement to our state-of-the-art autologous ActiGraft," said Alon Kushnir, Chief Executive Officer of RedDress. "We are excited and proud to partner with Legacy to provide the best options to those who are suffering from chronic, non-healing wounds."

LMC's portfolio already includes six products, Zenith Amniotic Allograft, Impax Amniotic Allograft, Orion Amniotic Allograft, Complete ACA Allograft, SurGraft FT Allograft, and Reeva FT Allograft.

Availability

ActiGraft is available for order today through Legacy Medical's Customer Service Department ([email protected]) or by calling 817-961-1288. Existing RedDress customers will transition automatically and experience no disruption in supply or support.

About RedDress

RedDress is a privately held biomedical company dedicated to transforming wound care through autologous, patient‑centric solutions. U.S. Headquartered in Jacksonville, Florida, RedDress holds multiple patents around its proprietary blood‑clot technology and is committed to advancing clinical evidence in chronic‑wound management. Learn more at www.reddressmedical.com.

About Legacy Medical Consultants

Legacy Medical Consultants elevates patient care by addressing unmet clinical needs in wound patients. LMC's team of dedicated professionals serves both providers and their patients in the field of complex wound care. To learn more about LMC's portfolio of products please visit https://www.legacymedicalconsultants.com/.

References: